GSK (GSK): news on Tuesday 20 October 2026

The 37 stories

Each headline's own score, strongest first. Links go to the publisher.

• +10.0 Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer GSK US
  First and only immunotherapy approved for this rectal cancer.
• +10.0 GSK’s Jemperli scores FDA approval in rectal cancer, backed by high complete response rate Fierce Pharma
  Approval backed by high complete response rate.
• +10.0 GSK's Jemperli gets US nod for biomarker-defined rectal cancer FirstWord Pharma
  US approval for biomarker-defined rectal cancer.
• +10.0 FDA approves GSK's Jemperli for a specific rectal cancer type StreetInsider
  FDA approves Jemperli for rectal cancer type.
• +9.7 FDA Approves GSK’s Jemperli for First-Line MSI-High, dMMR Rectal Cancer GenomeWeb
  FDA approves Jemperli first-line for rectal cancer.
• +9.7 FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Pharmaceutical Executive
  Accelerated approval for Jemperli in rectal cancer.
• +9.5 GSK's Jemperli Receives FDA Approval to Treat Some Patients With Advanced Rectal Cancer marketscreener.com
  Jemperli approved for some advanced rectal cancer patients.
• +9.5 FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated Benzinga
  FDA clears drug that could change rectal cancer treatment.
• +9.5 GSK’s Jemperli wins FDA approval for rectal cancer treatment Investing.com
  Jemperli wins FDA approval for rectal cancer.
• +9.2 Jefferies backs GSK with 2,500p target after positive lung cancer drug results Proactive financial news
  Jefferies backs GSK with high target after lung data.
• +9.2 GSK’s Jemperli Rectal Cancer Indication Becomes US FDA’s 11th National Priority Voucher Approval Pink Sheet
  Jemperli approval via FDA priority voucher.
• +9.2 Jefferies upgrades GSK with 34% upside after st... Pluang
  Jefferies upgrade with significant upside.
• +8.3 GSK Investing $800M in Biopharma Manufacturing in Pennsylvania New Jersey Business & Industry Association
  $800M manufacturing investment in Pennsylvania.
• +8.3 AnaptysBio Announces FDA Approval of GSK’s Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Based on AZUR-1 Data Quiver Quantitative
  Partner announces FDA approval of GSK's Jemperli.
• +8.3 A newly approved rectal cancer drug could help eligible patients avoid chemo, radiation and surgery Stock Titan
  New drug could spare patients chemo, radiation, surgery.
• +8.3 GSK to Invest $800M in Metro Philadelphia Life Sciences, Manufacturing Facilities, Create 300 New Jobs REBusinessOnline
  $800M investment creating 300 jobs.
• +7.5 What Do GSK (LSE:GSK) Oncology Wins Mean For Its Long Term Growth? Simply Wall Street
  Oncology wins framed positively for long-term growth.
• +7.5 GSK's Ris‑Rez shows 61pc response rate in early lung cancer study Sharecast.com
  61pc response rate in early lung cancer study.
• +7.5 Data reveal is promising for GSK's lung cancer drug ris-rez pharmaphorum
  Promising data for lung cancer drug.
• +7.5 AnaptysBio gains as GSK granted FDA label expansion for Jemperli Seeking Alpha
  Label expansion granted for Jemperli.
• +7.5 GSK plc : Jefferies reiterates its Buy rating marketscreener.com
  Jefferies reiterates Buy rating.
• +6.7 A 50-patient lung cancer analysis helps GSK (GSK) select a dose for its late-stage trial. Stock Titan
  Lung cancer analysis helps select late-stage dose.
• +6.7 AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo GuruFocus
  Partner's shares rise after GSK label expansion.
• +5.8 What Is GSK (LSE:GSK) Telling Investors With Its New Lung Cancer Data? Yahoo Finance
  New lung cancer data discussed for investors.
• +5.0 FTSE 100 GSK (LSE:GSK) Climbs as Defensive Buying Returns Kalkine Media
  Shares climb on defensive buying.
• +4.2 GSK Announces Ris-Rez Update October 19, 2026 James Sharp & Co.
  Ris-Rez update announced.
• +3.3 ESMO first look: Zai Lab, GSK, Merck and others detail wins, setbacks Endpoints News
  Mixed wins and setbacks across several companies at ESMO.
• +3.3 Four FDA Decisions in Two Weeks: GSK's Hepatitis B Drug Leads the Pack as Inovio Shares Have Already Fallen Over 40% This Year BigGo Finance
  Hepatitis B drug decision pending; mostly about Inovio.
• +3.3 RBC keeps GBp 1,975 target for GSK stock - ad-hoc-news.de ad-hoc-news.de
  RBC maintains price target.
• +2.5 Viola Davis Joins GSK Shingles Awareness Campaign 10/20/2026 MediaPost
  Celebrity joins shingles awareness campaign; minor marketing.
• +2.5 GSK, INO, AGIO And Sun Pharma Await Key FDA Rulings In October That Could Shape Their Drug Pipelines Stocktwits
  Upcoming FDA rulings listed alongside other companies.
• +2.0 GlaxoSmithKline (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are among a cluster of companies awaiting review, as U.S. innovative drugs enter an FDA approval window. Moomoo
  Awaiting FDA reviews alongside other companies.
• +1.7 Kristian Jensen Announces New Global Lung Cancer Medical Affairs Position at GSK Oncodaily
  Executive appointment in lung cancer medical affairs.
• +1.7 GSK stock: Dividend yield for GSK stock stands at 4.00 percent - ad-hoc-news.de ad-hoc-news.de
  Dividend yield factual note.
• +1.7 GSK, Inovio, and Agios Drug Approval Updates Intellectia AI
  Drug approval updates, grouped with other firms.
• +1.7 FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings TradingView
  Upcoming drug rulings overview including GSK.
• −1.7 GSK consolidates as overbought conditions hint at limited upside Traders Union
  Overbought conditions hint at limited upside.